OVARIAN SEROUS CYSTADENOCARCINOMA
Clinical trials for OVARIAN SEROUS CYSTADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OVARIAN SEROUS CYSTADENOCARCINOMA trials appear
Sign up with your email to follow new studies for OVARIAN SEROUS CYSTADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether adding the experimental drug AZD1775 to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 participants will receive either the combination…
Matched conditions: OVARIAN SEROUS CYSTADENOCARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug duo targets Hard-to-Treat brain tumors
Disease control OngoingThis early-phase trial tests a new drug (MLN0128) combined with bevacizumab in people with recurrent glioblastoma (a brain cancer) or other advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the safest dose and understand side ef…
Matched conditions: OVARIAN SEROUS CYSTADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:50 UTC